Revenue
2023
2024
2025
Septerna, Inc. (SEPN)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $46.0M | $1.1M | $151,000 |
| Research & development | $97.6M | $65.3M | $36.0M |
| Operating expenses | $114.2M | $81.9M | — |
| Operating income | −$68.3M | −$80.8M | $2.1M |
| EBITDAderived | −$66.7M | −$79.4M | $2.9M |
| Net income | −$48.9M | −$71.8M | $4.2M |
| Basic EPSper diluted share | -$1.10 | -$7.26 | $0.29 |
| Diluted EPSper diluted share | -$1.10 | -$7.26 | $0.29 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Shaikhly SamiraChief People Officer | SellCommon Stock | 2.2K | $35.18 | $76.6K | 793 |
| Jun 22, 2026Form 4 · 10b5-1 | Long Daniel D.SVP, Drug Discovery | SellCommon Stock | 7.0K | $35.97 | $251.8K | 96.4K |
| Jun 22, 2026Form 4 · 10b5-1 | Long Daniel D.SVP, Drug Discovery | SellCommon Stock | 8.0K | $35.10 | $280.8K | 103.4K |
| Jun 12, 2026Form 4 · 10b5-1 | Shaikhly SamiraChief People Officer | SellCommon Stock | 6.3K | $35.08 | $219.3K | 793 |
| Jun 1, 2026Form 4 · 10b5-1 | Shaikhly SamiraChief People Officer | SellCommon Stock | 2.9K | $29.66 | $85.7K | 793 |